プレガバリンの市場規模、シェア、成長分析、剤形別、用途別、薬剤クラス別、流通チャネル別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

プレガバリンの世界市場規模は2023年に19億米ドルと評価され、2024年の19億7,000万米ドルから2032年には26億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは3.8％で成長する見通しです。

世界のプレガバリン市場は、てんかん、神経障害性疼痛、線維筋痛症、不安などの神経疾患の有病率の上昇、特に25～60歳の成人の間で顕著な成長が見られます。WHOによると、てんかん患者は世界で5,000万人を超えており、適切な治療を受ければ70％が発作のない生活を送れる可能性があります。成人はこれらの慢性疾患に対する感受性が高いため、依然として主要な消費者グループです。さらに、低所得層や十分な治療を受けていない地域でのアクセスを改善するための主要企業の戦略的取り組みが、市場の拡大を後押ししています。低所得国ではてんかん患者の約75～90%が十分な治療を受けておらず、このアンメットニーズへの対応が大きな成長機会となっています。対象人口の増加と世界の疾病負担の増加は、引き続きプレガバリン治療薬に対する市場の需要を促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

プレガバリン市場規模：剤形別& CAGR（2025-2032）

• 市場概要
• 経口カプセル
• 経口溶液
• 経口錠
• 徐放製剤

プレガバリン市場規模：用途別& CAGR（2025-2032）

• 市場概要
• てんかん
• 神経障害性疼痛
• 不安障害
• その他

プレガバリン市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 線維筋痛症治療薬
• 抗けいれん薬
• その他

プレガバリン市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

プレガバリン市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• ホームケア
• その他

プレガバリン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Pfizer Inc.（U.S.）
• GSK plc（U.K.）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Zydus Cadila（India）
• Lupin（India）
• Amneal Pharmaceuticals LLC.（U.S.）
• Cipla Inc.（U.S.）
• Torrent Pharmaceuticals Ltd.（India）
• Aurobindo Pharma Limited（India）
• Glenmark Pharmaceuticals Limited（India）
• Medley Pharmaceuticals Ltd.（India）
• Genesisbiotec（India）
• Biomax Biotechnics（India）

結論と提言

Global Pregabalin Market size was valued at USD 1.9 billion in 2023 and is poised to grow from USD 1.97 billion in 2024 to USD 2.66 billion by 2032, growing at a CAGR of 3.8% during the forecast period (2025-2032).

The global pregabalin market is witnessing significant growth driven by the rising prevalence of neurological conditions such as epilepsy, neuropathic pain, fibromyalgia, and anxiety, especially among adults aged 25 to 60. According to WHO, over 50 million people suffer from epilepsy globally, with up to 70% potentially living seizure-free if properly treated. Adults remain the dominant consumer group due to their higher susceptibility to these chronic disorders. Additionally, strategic initiatives by key players to improve access in low-income and underserved regions are bolstering market expansion. With around 75-90% of epilepsy patients in low-income countries lacking adequate treatment, addressing this unmet need presents a major growth opportunity. The growing target population and increasing global disease burden continue to fuel market demand for pregabalin therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pregabalin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pregabalin Market Segments Analysis

Global Pregabalin Market is segmented by Forms, Application, Drug Class, Distribution Channel, End User and region. Based on Forms, the market is segmented into Oral Capsule, Oral Solution, Oral Tablet and Extended Release. Based on Application, the market is segmented into Epilepsy, Neuropathic Pain, Anxiety Disorder and Others. Based on Drug Class, the market is segmented into Fibromyalgia Agents, Anticonvulsants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pregabalin Market

The global pregabalin market is being significantly driven by the rising incidence of neuropathic pain and generalized anxiety disorders. Healthcare professionals in both developed and emerging markets are increasingly turning to pregabalin due to its dual therapeutic benefits for managing chronic pain as well as alleviating anxiety symptoms. In 2024, treatment guidelines in countries like Canada and Australia were updated to recognize pregabalin as a first-line option, further enhancing its adoption in both neurological and psychiatric treatments. This growing acceptance among medical practitioners is contributing to an upsurge in pregabalin's utilization worldwide, thereby expanding its market footprint.

Restraints in the Global Pregabalin Market

The global pregabalin market faces significant constraints primarily due to its classification as a controlled substance in many countries, which hampers its market growth. Regulatory restrictions, particularly concerning prescribing practices, stem from concerns about the drug's potential for abuse and dependence. This has resulted in a slower adoption rate within various healthcare settings, including general care units and outpatient services. For instance, in 2024, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) reaffirmed pregabalin's status as a Schedule 3 medication, which imposes stricter prescription controls and additional record-keeping requirements, further deterring its use among outpatients and primary care providers.

Market Trends of the Global Pregabalin Market

The global pregabalin market is witnessing a robust upward trend, driven by the rising demand for effective neuropathic pain relief solutions. As chronic pain conditions, particularly among aging populations in North America and Europe, become more prevalent, pregabalin, notably branded as Lyrica, has emerged as a go-to therapeutic option for managing ailments such as diabetic neuropathy and post-herpetic neuralgia. To cater to this increasing demand, pharmaceutical companies are innovating by introducing specialized dosage and long-acting formulations. Notably, Pfizer has enhanced its Lyrica CR line with a new formulation specifically designed for geriatric patients, addressing crucial issues of tolerability and compliance, further propelling market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Pregabalin Market Size by Forms & CAGR (2025-2032)

• Market Overview
• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Fibromyalgia Agents
• Anticonvulsants
• Others

Global Pregabalin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market Size & CAGR (2025-2032)

• North America (Forms, Application, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Forms, Application, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Forms, Application, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Forms, Application, Drug Class, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Forms, Application, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (U.K.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals LLC. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medley Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesisbiotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomax Biotechnics (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations